Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism
- 31 December 1995
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 23 (6), 712-719
- https://doi.org/10.1016/0168-8278(95)80038-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Controlled trial of tamoxifen in patients with advanced hepatocellular carcinomaJournal of Hepatology, 1994
- The unliganded estrogen receptor (ER) transduces growth factor signalsThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Sex hormone receptors in hepatocellular carcinoma: Is there a rationale for hormonal treatment?Journal of Hepatology, 1993
- Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liverDigestive Diseases and Sciences, 1991
- An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassayFundamental and Applied Toxicology, 1991
- Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifenJournal of Hepatology, 1990
- Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case/control study in south african black womenHepatology, 1990
- Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donorCell, 1978